Zai Lab (ZLAB) announced the FDA has granted fast track designation to ZL-1310, the company’s Delta-like ligand antibody-drug conjugate, for the treatment of extensive-stage small cell lung cancer. ZL-1310, which is being evaluated in an ongoing global Phase 1a/1b clinical trial, previously received an Orphan Drug designation for SCLC from the FDA. The company will present updated data at the 2025 American Society of Clinical Oncology annual meeting.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
- Zai Lab’s Growth Amidst Competitive Pressures: Analyst Recommends Hold
- Zai Lab Ltd’s Earnings Call Highlights Strong Growth and Promising Pipeline
- Zai Lab’s Promising Pipeline and Strategic Advancements Drive Positive Outlook Despite Q1 Revenue Miss
- Zai Lab’s Growth Potential: Strong Revenue Projections and Strategic Positioning Drive Buy Rating
- Zai Lab: Hold Rating Amid Mixed Financial Performance and Cautious Outlook